A candidate serum biomarker for bladder pain syndrome/interstitial cystitis.

Analyst

Department of Food Science and Technology, College of Food, Agriculture and Environmental Sciences, The Ohio State University, Columbus, Ohio, USA.

Published: June 2009

Reliable diagnostic markers for Bladder Pain Syndrome/Interstitial Cystitis (IC) currently are not available. This study evaluated the feasibility of diagnosing IC in humans and domestic cats from the spectra of dried serum films (DSFs) using infrared microspectroscopy. Spectra were obtained from films from 29 humans and 34 domestic cats to create classification models using Soft Independent Modeling by Class Analogy (SIMCA). Ultrafiltration of serum improved discrimination capability. The classification models for both species successfully classified spectra based on condition (healthy/sick), and a different set of masked spectra correctly predicted the condition of 100% of the subjects. Classification required information from the 1500-1800 cm(-1) spectral region to discriminate between subjects with IC, other disorders, and healthy subjects. Analysis of cat samples using liquid chromatography-mass spectroscopy revealed differences in the concentration of tryptophan and its metabolites between healthy and affected cats. These results demonstrate the potential utility of infrared microspectroscopy to diagnose IC in both humans and cats.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3852842PMC
http://dx.doi.org/10.1039/b901736dDOI Listing

Publication Analysis

Top Keywords

bladder pain
8
pain syndrome/interstitial
8
syndrome/interstitial cystitis
8
humans domestic
8
domestic cats
8
infrared microspectroscopy
8
classification models
8
candidate serum
4
serum biomarker
4
biomarker bladder
4

Similar Publications

Contribution of the Microbiome to Interstitial Cystitis/Bladder Pain Syndrome: A Mini Review.

Eur Urol Focus

January 2025

Medical School of Nantong University, Nantong, China; Department of Urology, Jiangnan University Medical Center, Wuxi, China. Electronic address:

Interstitial cystitis/bladder pain syndrome (IC/BPS) is a chronic and debilitating condition characterized by pelvic pain and urinary urgency and frequency with an unclear etiology. Emerging evidence implicates microbiome dysbiosis-disruptions in the microbial communities inhabiting the body-in IC/BPS pathophysiology. This review synthesizes the literature on microbial alterations in IC/BPS, including urinary, vaginal, and gastrointestinal microbiota, and their interactions with host inflammatory and metabolic pathways.

View Article and Find Full Text PDF
Article Synopsis
  • Lumbar fusion and lumbar disk replacement (LDR) are common surgical options for chronic low back pain, but this study focused on comparing their postoperative management costs over two years.
  • A total of 1,660 patients were studied, revealing that the average cost for postoperative care was approximately $2,832 per patient, with similar costs for both procedures.
  • The main cost driver was physical therapy, highlighting that while LDR may have a shorter recovery, it does not significantly reduce long-term healthcare expenses compared to lumbar fusion.
View Article and Find Full Text PDF

Purpose: Urinary cytokine changes may serve as biomarkers to assess treatment outcomes for interstitial cystitis/bladder pain syndrome (IC/BPS). This study analyzed the changes in urinary cytokines following various bladder therapies and explored their clinical significance in therapeutic mechanisms.

Methods: A total of 122 patients with IC/BPS treated with platelet-rich plasma (PRP), botulinum toxin-A (BoTN-A), hyaluronic acid (HA), or low-energy shock wave (LESW) were evaluated.

View Article and Find Full Text PDF

Objective: This case report discusses the diagnostic challenges associated with the early identification of cauda equina syndrome in a 25-year-old patient without lumbar spinal pain. It introduces a new classification scheme related to a more effective diagnosis.

Clinical Features: The patient experienced pain in the right hamstring, diagnosed as a pulled muscle.

View Article and Find Full Text PDF

Background: Bacillus Calmette-Guerin (BCG) immunotherapy is the standard adjuvant treatment for high-risk, non-muscle invasive bladder cancer (NMIBC). However, BCG immunotherapy is commonly accompanied by significant lower urinary tract symptoms (LUTS) including symptoms such as urinary urgency, frequency, dysuria and pelvic pain. These symptoms can undermine treatment adherence and clinical outcomes.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!